NexgenRx Announces Declaration of Dividend
NexgenRx Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / June 15, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding. The common shares are listed and posted for trading on the TSX Venture Exchange under the symbol 'NXG'. The series 1 preferred shares are not listed or posted for trading on any stock exchange.
多倫多，on/ACCESSWIRE/2023年6月15日/NEXGENRX Inc.NexgenRx(“NexgenRx”或“公司”)高興地宣佈，已宣佈就其所有已發行普通股和系列1優先股派發每股0.5美分(0.005美元)的股息。這筆股息將於2023年6月30日或之前支付給截至2023年6月23日收盤時登記在冊的所有股東。截至本新聞稿日期，共有70,335,883股普通股和6,600,000股系列1優先股已發行和流通。普通股在多倫多證券交易所創業板上市，交易代碼為“NXG”。第一系列優先股不在任何證券交易所上市或張貼交易。
About NexgenRx
NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software As a Service) Model.
關於NexgenRx
NexgenRx是加拿大唯一一家獨立的全方位服務第三方管理和技術解決方案提供商，提供專有的全面前端、資格、註冊、小時銀行和移動接入功能，以及最先進的索賠裁決和全面的提供商網路覆蓋。這些綜合能力使NexgenRx能夠以具有成本效益的SaaS(軟體即服務)模式為計劃發起人、複雜的管理和健康福利技術應用程式提供服務。
NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at .
NexgenRx致力於與希望超越其客戶和計劃成員期望的組織建立合作夥伴關係，並以具有競爭力的成本提供卓越的管理和索賠處理解決方案。有關NexgenRx的更多資訊，請訪問。
Caution Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The Company cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
有關前瞻性陳述的注意事項
除了對歷史事實的陳述外，本新聞稿還包含適用證券法意義上的某些“前瞻性資訊”。前瞻性資訊的特點常常是“計劃”、“預期”、“專案”、“打算”、“相信”、“預期”、“估計”等類似詞語，或某些事件或條件“可能”或“將”發生的陳述。儘管管理層認為前瞻性資訊中反映的預期是合理的，但不能保證這種預期將被證明是正確的。本公司不能保證未來的結果、業績或成就。因此，沒有證據表明所取得的實際成果將全部或部分與前瞻性資訊中所述的結果相同。
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether the Company's strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company's proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in the Company's annual Management's Discussion and Analysis, as filed under the Company's profile on SEDAR at . Readers are cautioned that this list of risk factors should not be construed as exhaustive.
前瞻性資訊基於管理層在作出陳述之日的意見和估計，受各種風險、不確定因素和其他因素的影響，這些因素可能會導致實際事件或結果與前瞻性資訊中預期的大不相同。可能導致結果與前瞻性資訊中表述的結果大不相同的一些風險和其他因素包括但不限於：公司的戰略和業務計劃是否會產生預期的收益的不確定性；資金的可用性和成本；識別和開發現有和新的產品和技術並取得商業成功的能力；維持和提高產品和服務質量所需的支出水準；技術和法律法規的變化；公司專有軟體技術的持續開發和增強；網路安全風險以及在公司年度管理層討論和分析中披露的其他風險和不確定因素，如公司在SEDAR上的簡介所述。提醒讀者，這份風險因素清單不應被解釋為詳盡無遺。
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. The Company undertakes no duty to update any of the forward-looking information to conform such information to actual results or to changes in the Company's expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
本新聞稿中包含的前瞻性資訊明確地受到這一警示聲明的限制。除非適用的證券法規另有要求，否則公司沒有義務更新任何前瞻性資訊，以使這些資訊與實際結果或公司預期的變化保持一致。告誡讀者不要過度依賴前瞻性資訊。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對新聞稿的充分性或準確性承擔責任。
FOR FURTHER INFORMATION PLEASE CONTACT:
Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801
欲瞭解更多資訊，請聯繫：
羅納德·C·盧克斯
NexgenRx Inc.
總裁與首席執行官
416.695.3393 x801
Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393x803
凱利·埃勒註冊會計師，加利福尼亞州
NexgenRx Inc.
首席財務官
416-695-3393x803
SOURCE: NexgenRx Inc.
資料來源：NexgenRx Inc.
譯文內容由第三人軟體翻譯。